Last Price
2.87
Today's Change
-0.01 (0.34%)
Day's Change
2.84 - 2.97
Trading Volume
901,941
Market Cap
444 Million
Shares Outstanding
154 Million
Avg Volume
1,027,327
Avg Price (50 Days)
3.33
Avg Price (200 Days)
3.76
PE Ratio
-9.57
EPS
-0.30
Earnings Announcement
26-Mar-2025
Previous Close
2.88
Open
2.95
Day's Range
2.84 - 2.97
Year Range
2.525 - 5.02
Trading Volume
901,941
1 Day Change
-0.35%
5 Day Change
-7.72%
1 Month Change
-5.28%
3 Month Change
-18.70%
6 Month Change
-29.66%
Ytd Change
-16.08%
1 Year Change
-22.22%
3 Year Change
111.03%
5 Year Change
75.29%
10 Year Change
-55.85%
Max Change
-55.85%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.